Cortisol metabolism in hypertension

Ferriss, 1978, Low-renin (“primary”) hyperaldosteronism. Differential diagnosis and distinction of sub-groups within the syndrome, American Heart Journal, 95, 641, 10.1016/0002-8703(78)90307-1 Stowasser, 2003, Primary aldosteronism, Best Practice & Research. Clinical Endocrinology and Metabolism, 17, 591, 10.1016/S1521-690X(03)00050-2 Tomlinson, 2004, 11beta-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response, Endocrine Reviews, 25, 831, 10.1210/er.2003-0031 Draper, 2005, 11beta-hydroxysteroid dehydrogenase and the pre-receptor regulation of corticosteroid hormone action, The Journal of Endocrinology, 186, 251, 10.1677/joe.1.06019 Ricketts, 1998, Immunohistochemical localization of type 1 11beta-hydroxysteroid dehydrogenase in human tissues, The Journal of Clinical Endocrinology and Metabolism, 83, 1325, 10.1210/jc.83.4.1325 Ozols, 1995, Lumenal orientation and post-translational modifications of the liver microsomal 11 beta-hydroxysteroid dehydrogenase, The Journal of Biological Chemistry, 270, 2305, 10.1074/jbc.270.5.2305 Lavery, 2006, Hexose-6-phosphate dehydrogenase Knock-out mice lack 11beta-hydroxysteroid dehydrogenase type 1-mediated glucocorticoid generation, The Journal of Biological Chemistry, 281, 6546, 10.1074/jbc.M512635200 Stewart, 1994, Human kidney 11 beta-hydroxysteroid dehydrogenase is a high affinity nicotinamide adenine dinucleotide-dependent enzyme and differs from the cloned type I isoform, The Journal of Clinical Endocrinology and Metabolism, 79, 480, 10.1210/jc.79.2.480 Shams, 1998, 11Beta-hydroxysteroid dehydrogenase type 2 in human pregnancy and reduced expression in intrauterine growth restriction, Human Reproduction (Oxford, England), 13, 799, 10.1093/humrep/13.4.799 Funder, 1988, Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated, Science, 242, 583, 10.1126/science.2845584 Wilson, 2001, Apparent mineralocorticoid excess, Trends in Endocrinology and Metabolism, 12, 104, 10.1016/S1043-2760(00)00356-8 White, 1997, 11 Beta-hydroxysteroid dehydrogenase and the syndrome of apparent mineralocorticoid excess, Endocrine Reviews, 18, 135, 10.1210/er.18.1.135 Dave-Sharma, 1998, Examination of genotype and phenotype relationships in 14 patients with apparent mineralocorticoid excess, The Journal of Clinical Endocrinology and Metabolism, 83, 2244, 10.1210/jc.83.7.2244 Ulick, 1979, A syndrome of apparent mineralocorticoid excess associated with defects in the peripheral metabolism of cortisol, The Journal of Clinical Endocrinology and Metabolism, 49, 757, 10.1210/jcem-49-5-757 Shackleton, 1985, Congenital 11 beta-hydroxysteroid dehydrogenase deficiency associated with juvenile hypertension: corticosteroid metabolite profiles of four patients and their families, Clinical Endocrinology (Oxford), 22, 701, 10.1111/j.1365-2265.1985.tb00160.x Monder, 1986, The syndrome of apparent mineralocorticoid excess: its association with 11 beta-dehydrogenase and 5 beta-reductase deficiency and some consequences for corticosteroid metabolism, The Journal of Clinical Endocrinology and Metabolism, 63, 550, 10.1210/jcem-63-3-550 Stewart, 1988, Syndrome of apparent mineralocorticoid excess. A defect in the cortisol-cortisone shuttle, The Journal of Clinical Investigation, 82, 340, 10.1172/JCI113592 Wilson, 1998, A genetic defect resulting in mild low-renin hypertension, Proceedings of the National Academy of Sciences of the U S A, 95, 10200, 10.1073/pnas.95.17.10200 Ulick, 1990, Pathogenesis of the type 2 variant of the syndrome of apparent mineralocorticoid excess, The Journal of Clinical Endocrinology and Metabolism, 70, 200, 10.1210/jcem-70-1-200 Mantero, 1996, Apparent mineralocorticoid excess: type I and type II, Steroids, 61, 193, 10.1016/0039-128X(96)00012-8 Palermo, 1998, Cure of apparent mineralocorticoid excess by kidney transplantation, The New England Journal of Medicine, 339, 1787, 10.1056/NEJM199812103392414 Albiston, 1994, Cloning and tissue distribution of the human 11 beta-hydroxysteroid dehydrogenase type 2 enzyme, Molecular and Cellular Endocrinology, 105, R11, 10.1016/0303-7207(94)90176-7 Agarwal, 1995, Gene structure and chromosomal localization of the human HSD11K gene encoding the kidney (type 2) isozyme of 11 beta-hydroxysteroid dehydrogenase, Genomics, 29, 195, 10.1006/geno.1995.1231 Quinkler, 2003, Hypertension and the cortisol-cortisone shuttle, The Journal of Clinical Endocrinology and Metabolism, 88, 2384, 10.1210/jc.2003-030138 Mune, 1995, Human hypertension caused by mutations in the kidney isozyme of 11 beta-hydroxysteroid dehydrogenase, Nature Genetics, 10, 394, 10.1038/ng0895-394 Wilson, 1995, Several homozygous mutations in the gene for 11 beta-hydroxysteroid dehydrogenase type 2 in patients with apparent mineralocorticoid excess, The Journal of Clinical Endocrinology and Metabolism, 80, 3145, 10.1210/jc.80.11.3145 Wilson, 1995, A mutation in the HSD11B2 gene in a family with apparent mineralocorticoid excess, The Journal of Clinical Endocrinology and Metabolism, 80, 2263, 10.1210/jc.80.7.2263 Stewart, 1996, Hypertension in the syndrome of apparent mineralocorticoid excess due to mutation of the 11 beta-hydroxysteroid dehydrogenase type 2 gene, Lancet, 347, 88, 10.1016/S0140-6736(96)90211-1 Kitanaka, 1997, A new compound heterozygous mutation in the 11 beta-hydroxysteroid dehydrogenase type 2 gene in a case of apparent mineralocorticoid excess, The Journal of Clinical Endocrinology and Metabolism, 82, 4054, 10.1210/jc.82.12.4054 Lavery, 2003, Late-onset apparent mineralocorticoid excess caused by novel compound heterozygous mutations in the HSD11B2 gene, Hypertension, 42, 123, 10.1161/01.HYP.0000083340.57063.35 Nunez, 1999, Mutants of 11beta-hydroxysteroid dehydrogenase (11-HSD2) with partial activity: improved correlations between genotype and biochemical phenotype in apparent mineralocorticoid excess, Hypertension, 34, 638, 10.1161/01.HYP.34.4.638 Li, 1997, Apparent mineralocorticoid excess in a Brazilian kindred: hypertension in the heterozygote state, Journal of Hypertension, 15, 1397, 10.1097/00004872-199715120-00005 Card, 1953, Effects of liquorice and its derivatives on salt and water metabolism, Lancet, 1, 663, 10.1016/S0140-6736(53)91801-7 Farese, 1991, Licorice-induced hypermineralocorticoidism, The New England Journal of Medicine, 325, 1223, 10.1056/NEJM199110243251706 Conn, 1968, Licorice-induced pseudoaldosteronism. Hypertension, hypokalemia, aldosteronopenia, and suppressed plasma renin activity, The Journal of the American Medical Association, 205, 492, 10.1001/jama.205.7.492 Stewart, 1987, Mineralocorticoid activity of liquorice: 11-beta-hydroxysteroid dehydrogenase deficiency comes of age, Lancet, 2, 821, 10.1016/S0140-6736(87)91014-2 Kageyama, 1992, Glycyrrhizin induces mineralocorticoid activity through alterations in cortisol metabolism in the human kidney, The Journal of Endocrinology, 135, 147, 10.1677/joe.0.1350147 Morris, 1992, Detection of glycyrrhetinic acid-like factors (GALFs) in human urine, Hypertension, 20, 356, 10.1161/01.HYP.20.3.356 Lo, 1997, Kidney 11 beta-HSD2 is inhibited by glycyrrhetinic acid-like factors in human urine, Hypertension, 29, 500, 10.1161/01.HYP.29.1.500 Walker, 1995, Endogenous inhibitors of 11 beta-hydroxysteroid dehydrogenase in hypertension, The Journal of Clinical Endocrinology and Metabolism, 80, 529, 10.1210/jc.80.2.529 Palermo, 1996, Urinary free cortisone and the assessment of 11 beta-hydroxysteroid dehydrogenase activity in man, Clinical Endocrinology (Oxford), 45, 605, 10.1046/j.1365-2265.1996.00853.x Beretta-Piccoli, 1983, Relation of blood pressure with body and plasma electrolytes in Conn's syndrome, Journal of Hypertension, 1, 197, 10.1097/00004872-198308000-00014 Walker, 1993, Deficient inactivation of cortisol by 11 beta-hydroxysteroid dehydrogenase in essential hypertension, Clinical Endocrinology (Oxford), 39, 221, 10.1111/j.1365-2265.1993.tb01778.x Soro, 1995, Evidence of coexisting changes in 11 beta-hydroxysteroid dehydrogenase and 5 beta-reductase activity in subjects with untreated essential hypertension, Hypertension, 25, 67, 10.1161/01.HYP.25.1.67 Walker, 2001, Steroid metabolism in metabolic syndrome X, Best Practice & Research. Clinical Endocrinology and Metabolism, 15, 111, 10.1053/beem.2000.0123 Walker, 1998, Increased glucocorticoid activity in men with cardiovascular risk factors, Hypertension, 31, 891, 10.1161/01.HYP.31.4.891 Mariniello, 2005, Analysis of the 11beta-hydroxysteroid dehydrogenase type 2 gene (HSD11B2) in human essential hypertension, American Journal of Hypertension, 18, 1091, 10.1016/j.amjhyper.2005.02.020 Watson, 1996, Genetic association of 11 beta-hydroxysteroid dehydrogenase type 2 (HSD11B2) flanking microsatellites with essential hypertension in blacks, Hypertension, 28, 478, 10.1161/01.HYP.28.3.478 Smolenicka, 1998, A new polymorphic restriction site in the human 11 beta-hydroxysteroid dehydrogenase type 2 gene, The Journal of Clinical Endocrinology and Metabolism, 83, 1814, 10.1210/jc.83.5.1814 Brand, 1998, Structural analysis and evaluation of the 11beta-hydroxysteroid dehydrogenase type 2 (11beta-HSD2) gene in human essential hypertension, Journal of Hypertension, 16, 1627, 10.1097/00004872-199816110-00009 Williams, 2005, Role of HSD11B2 polymorphisms in essential hypertension and the diuretic response to thiazides, Kidney International, 67, 631, 10.1111/j.1523-1755.2005.67119.x Lovati, 1999, Molecular basis of human salt sensitivity: the role of the 11beta-hydroxysteroid dehydrogenase type 2, The Journal of Clinical Endocrinology and Metabolism, 84, 3745, 10.1210/jc.84.10.3745 Agarwal, 2000, CA-Repeat polymorphism in intron 1 of HSD11B2: effects on gene expression and salt sensitivity, Hypertension, 36, 187, 10.1161/01.HYP.36.2.187 Carvajal, 2005, Biochemical and genetic characterization of 11 beta-hydroxysteroid dehydrogenase type 2 in low-renin essential hypertensives, Journal of Hypertension, 23, 71, 10.1097/00004872-200501000-00015 White, 2001, Possible association but no linkage of the HSD11B2 gene encoding the kidney isozyme of 11beta-hydroxysteroid dehydrogenase to hypertension in Black people, Clinical Endocrinology (Oxford), 55, 249, 10.1046/j.1365-2265.2001.01314.x Kadowitz, 1971, Influence of hydrocortisone on cardiovascular responses to epinephrine, European Journal of Pharmacology, 13, 281, 10.1016/0014-2999(71)90215-9 Yard, 1972, Studies on the mechanism of hydrocortisone potentiation of vasoconstrictor responses to epinephrine in the anesthetized animal, European Journal of Pharmacology, 20, 1, 10.1016/0014-2999(72)90209-9 Briegel, 1999, Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study, Critical Care Medicine, 27, 723, 10.1097/00003246-199904000-00025 Annane, 1998, Impaired pressor sensitivity to noradrenaline in septic shock patients with and without impaired adrenal function reserve, British Journal of Clinical Pharmacology, 46, 589, 10.1046/j.1365-2125.1998.00833.x Fowler, 1961, Potentiation of smooth muscle contraction by adrenal steroids, Circulation Research, 9, 153, 10.1161/01.RES.9.1.153 Sakaue, 1991, Glucocorticoids induce transcription and expression of the alpha 1B adrenergic receptor gene in DTT1 MF-2 smooth muscle cells, The Journal of Clinical Investigation, 88, 385, 10.1172/JCI115315 Ullian, 1996, Potentiation of angiotensin II action by corticosteroids in vascular tissue, Cardiovascular Research, 32, 266, 10.1016/0008-6363(96)00053-3 Scott, 1987, Aldosterone and dexamethasone binding in human arterial smooth muscle cells, Journal of Hypertension, 5, 739, 10.1097/00004872-198712000-00018 Brem, 1995, Bidirectional activity of 11 beta-hydroxysteroid dehydrogenase in vascular smooth muscle cells, Steroids, 60, 406, 10.1016/0039-128X(94)00074-M Alzamora, 2000, Role of 11beta-hydroxysteroid dehydrogenase in nongenomic aldosterone effects in human arteries, Hypertension, 35, 1099, 10.1161/01.HYP.35.5.1099 Brem, 1997, Effects of licorice derivatives on vascular smooth muscle function, Life Sciences, 60, 207 Souness, 2002, 11 Beta-hydroxysteroid dehydrogenase antisense affects vascular contractile response and glucocorticoid metabolism, Steroids, 67, 195, 10.1016/S0039-128X(01)00148-9 Muto, 1998, Corticosterone and 11-dehydrocorticosterone stimulate Na,K-ATPase gene expression in vascular smooth muscle cells, Kidney International, 54, 492, 10.1046/j.1523-1755.1998.00033.x Whitworth, 2002, The nitric oxide system in glucocorticoid-induced hypertension, Journal of Hypertension, 20, 1035, 10.1097/00004872-200206000-00003 Brem, 1998, Localization of 2 11beta-OH steroid dehydrogenase isoforms in aortic endothelial cells, Hypertension, 31, 459, 10.1161/01.HYP.31.1.459 Quaschning, 2001, Aldosterone receptor antagonism normalizes vascular function in liquorice-induced hypertension, Hypertension, 37, 801, 10.1161/01.HYP.37.2.801 Hadoke, 2001, Endothelial cell dysfunction in mice after transgenic knockout of type 2, but not type 1, 11beta-hydroxysteroid dehydrogenase, Circulation, 104, 2832, 10.1161/hc4801.100077 Kayes-Wandover, 2000, Steroidogenic enzyme gene expression in the human heart, The Journal of Clinical Endocrinology and Metabolism, 85, 2519, 10.1210/jc.85.7.2519 Pitt, 1999, The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators, The New England Journal of Medicine, 341, 709, 10.1056/NEJM199909023411001 Pitt, 2003, Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction, The New England Journal of Medicine, 348, 1309, 10.1056/NEJMoa030207 Funder, 2004, Is aldosterone bad for the heart?, Trends in Endocrinology and Metabolism, 15, 139, 10.1016/j.tem.2004.03.006 Qin, 2003, Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure, Circulation Research, 93, 69, 10.1161/01.RES.0000080521.15238.E5 Kotelevtsev, 1997, 11Beta-hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress, Proceedings of the National Academy of Sciences of the U S A, 94, 14924, 10.1073/pnas.94.26.14924 Gomez-Sanchez, 2004, Brain mineralocorticoid receptors: orchestrators of hypertension and end-organ disease, Current Opinion in Nephrology and Hypertension, 13, 191, 10.1097/00041552-200403000-00007 Gomez-Sanchez, 1990, ICV infusion of corticosterone antagonizes ICV-aldosterone hypertension, The American Journal of Physiology, 258, E649 Seckl, 1997, 11Beta-hydroxysteroid dehydrogenase in the brain: a novel regulator of glucocorticoid action?, Frontiers in Neuroendocrinology, 18, 49, 10.1006/frne.1996.0143 De Kloet, 2000, Brain mineralocorticoid receptors and centrally regulated functions, Kidney International, 57, 1329, 10.1046/j.1523-1755.2000.00971.x Gomez-Sanchez, 1992, Central hypertensinogenic effects of glycyrrhizic acid and carbenoxolone, The American Journal of Physiology, 263, E1125 Zhang, 2006, 11{Beta}-hydroxysteroid dehydrogenase type 2 activity in hypothalamic paraventricular nucleus modulates sympathetic excitation, Hypertension, 48, 127, 10.1161/01.HYP.0000224296.96235.dd Geerling, 2006, Aldosterone target neurons in the nucleus tractus solitarius drive sodium appetite, The Journal of Neuroscience, 26, 411, 10.1523/JNEUROSCI.3115-05.2006 Cooney, 1996, Increased sodium appetite and thirst in rat induced by the ingredients of liquorice, glycyrrhizic acid and glycyrrhetinic acid, Regulatory Peptides, 66, 127, 10.1016/0167-0115(96)00048-1 Barker, 1989, Growth in utero, blood pressure in childhood and adult life, and mortality from cardiovascular disease, British Medical Journal, 298, 564, 10.1136/bmj.298.6673.564 Law, 1996, Is blood pressure inversely related to birth weight? The strength of evidence from a systematic review of the literature, Journal of Hypertension, 14, 935, 10.1097/00004872-199608000-00002 Alexander, 2006, Fetal programming of hypertension, American Journal of Physiology. Regulatory, Integrative and Comparative Physiology, 290, R1, 10.1152/ajpregu.00417.2005 Seckl, 2004, Prenatal glucocorticoids and long-term programming, European Journal of Endocrinology, 151, U49, 10.1530/eje.0.151U049 Lindsay, 1996, Inhibition of 11-beta-hydroxysteroid dehydrogenase in pregnant rats and the programming of blood pressure in the offspring, Hypertension, 27, 1200, 10.1161/01.HYP.27.6.1200 Welberg, 2001, Prenatal glucocorticoid programming of brain corticosteroid receptors and corticotrophin-releasing hormone: possible implications for behaviour, Neuroscience, 104, 71, 10.1016/S0306-4522(01)00065-3 Ortiz, 2003, Prenatal dexamethasone programs hypertension and renal injury in the rat, Hypertension, 41, 328, 10.1161/01.HYP.0000049763.51269.51 Langley-Evans, 1996, Protein intake in pregnancy, placental glucocorticoid metabolism and the programming of hypertension in the rat, Placenta, 17, 169, 10.1016/S0143-4004(96)80010-5 Stewart, 1995, Type 2 11 beta-hydroxysteroid dehydrogenase messenger ribonucleic acid and activity in human placenta and fetal membranes: its relationship to birth weight and putative role in fetal adrenal steroidogenesis, The Journal of Clinical Endocrinology and Metabolism, 80, 885, 10.1210/jc.80.3.885 McTernan, 2001, Reduced placental 11beta-hydroxysteroid dehydrogenase type 2 mRNA levels in human pregnancies complicated by intrauterine growth restriction: an analysis of possible mechanisms, The Journal of Clinical Endocrinology and Metabolism, 86, 4979, 10.1210/jc.86.10.4979 Dodic, 2002, Programmed hypertension: kidney, brain or both?, Trends in Endocrinology and Metabolism, 13, 403, 10.1016/S1043-2760(02)00693-8